RxDoctor Payments Data

van Malia, DO

Interventional Pain Medicine · Augusta, GANPI 1740423243

Payments from drug & device makers

$588in general payments, 2019–2025

Across 23 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$377
  • Vertos Medical, Inc.$55
  • Curonix LLC$34
  • Scilex Pharmaceuticals Inc.$32
  • Medtronic$25
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$588100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$588 in reported general payments places this provider in the 15th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$88,733
Medicare patients
134
Services billed
1,516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate43$34,376
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen569$17,698
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen438$12,306
Oxycodone Hcl281$5,731
Pregabalin136$3,620
Diclofenac Sodium61$3,075
Gabapentin203$2,844
Cyclobenzaprine Hcl168$2,366
Morphine Sulfate ErMorphine Sulfate46$1,874
Tizanidine Hcl85$1,821
Methocarbamol63$1,516
Lidocaine18$1,241
Fentanyl14$1,137
Nortriptyline Hcl62$1,105
Hydromorphone Hcl46$1,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$20$34,37643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →